Xilio Therapeutics (XLO) Price & Analysis

Compare

211 Followers

XLO Stock Chart & Stats

$0.79

-$0.02(-1.59%)

At close: Jan 08 4:00 PM EST

$0.79

-$0.02(-1.59%)

Day’s Range― - ―

52-Week Range$0.62 - $1.70

Previous CloseN/A

Volume162.24K

Average Volume (3M)790.58K

Market Cap

$39.77M

Enterprise Value$24.94M

Total Cash (Recent Filing)$103.76M

Total Debt (Recent Filing)$7.26M

Price to Earnings (P/E)―

Beta-0.13

Next Earnings

Mar 04, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding52,500,328

10 Day Avg. Volume525,233

30 Day Avg. Volume790,583

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)2.90

Price to Sales (P/S)8.06

P/FCF Ratio-2.78

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue0.78

Enterprise Value/Gross Profit1.55

Enterprise Value/Ebitda-0.44

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentManagement aims to partner with other companies to advance the clinical development of vilastobart, showing a proactive approach in expanding potential market reach.

Financial StabilityThe company ended the quarter with $121.6M in cash and cash equivalents, which should sustain operations into 3Q26.

InnovationXilio is on track with strategic nominations for developing targeted therapies, reflecting a clear pipeline and focus on innovation.

Bears Say

Financial PerformanceXilio reported a net loss of $16.3 million, indicating financial challenges that need to be addressed.

Strategic PartnershipsFinding the right partner quickly is critical for both the asset and the company.

Xilio Therapeutics News

Xilio Therapeutics expects cash to fund operations into Q1 of 2027

Based on its current operating plans, Xilio anticipates that its cash and cash equivalents as of September 30,...

17d ago

XLO

Xilio Therapeutics reports Q3 EPS (11c) vs (22c) last year

Reports Q3 revenue $19.066M vs $2.263M last year. “As we advance our robust pipeline of innovative masked immunotherapies,...

17d ago

XLO

Xilio Therapeutics presents new data across portfolio at SITC

Xilio Therapeutics (XLO) announced new data across its portfolio, including preclinical data highlighting the potential for Xilio’s masked...

23d ago

XLO

Xilio Therapeutics announces new data on Phase 2 trial of vilastobart

Xilio Therapeutics (XLO) announced new data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced...

23d ago

XLO

Xilio Therapeutics Approves 2025 Stock Incentive Plan

The latest update is out from Xilio Therapeutics ( ($XLO) ). On November 21, 2025, Xilio Therapeutics held...

5d ago

XLO

Xilio Therapeutics Reports Revenue Growth Amidst Challenges

Xilio Therapeutics Inc ( ($XLO) ) has released its Q3 earnings. Here is a breakdown of the information...

13d ago

XLO

Xilio Therapeutics Transfers Listing to Nasdaq Capital Market

Xilio Therapeutics ( ($XLO) ) just unveiled an update. On October 2, 2025, Xilio Therapeutics received approval from...

2M ago

XLO

Xilio Therapeutics Initiates Phase 2 Trial for XTX301

Xilio Therapeutics ( ($XLO) ) has issued an announcement. On September 9, 2025, Xilio Therapeutics announced the initiation...

3M ago

XLO

Xilio Therapeutics announces initiation of Phase 2 trial for efarindodekin alfa

Xilio Therapeutics (XLO) announced the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical...

3M ago

XLO

GILD

Xilio Therapeutics sees cash runway into 1Q27

As of June 30, 2025, Xilio had cash and cash equivalents of $121.6M. Based on its current operating...

3M ago

XLO

Xilio Therapeutics Faces Nasdaq Equity Compliance Challenge

Xilio Therapeutics ( ($XLO) ) has shared an update. On August 22, 2025, Xilio Therapeutics, Inc. received a...

3M ago

XLO

Xilio Therapeutics Reports Strong Pipeline Progress and Financial Results

Xilio Therapeutics Inc ( ($XLO) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

XLO

Promising Future for Xilio Therapeutics: Strong Financial Position and Encouraging Trial Results Support Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on XLO stock, giving a Buy rating on...

4M ago

XLO

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

Reports Q2 revenue $8.084M vs $2.357M last year. “During the second quarter, we continued to make strong progress...

4M ago

XLO

XLO FAQ

What was Xilio Therapeutics Inc’s price range in the past 12 months?

Xilio Therapeutics Inc lowest stock price was $0.61 and its highest was $1.70 in the past 12 months.

What is Xilio Therapeutics Inc’s market cap?

Xilio Therapeutics Inc’s market cap is $39.77M.

When is Xilio Therapeutics Inc’s upcoming earnings report date?

Xilio Therapeutics Inc’s upcoming earnings report date is Mar 04, 2026 which is in 93 days.

How were Xilio Therapeutics Inc’s earnings last quarter?

Xilio Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.032 by -$0.078.

Is Xilio Therapeutics Inc overvalued?

According to Wall Street analysts Xilio Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xilio Therapeutics Inc pay dividends?

Xilio Therapeutics Inc does not currently pay dividends.

What is Xilio Therapeutics Inc’s EPS estimate?

Xilio Therapeutics Inc’s EPS estimate is -0.07.

How many shares outstanding does Xilio Therapeutics Inc have?

Xilio Therapeutics Inc has 52,500,328 shares outstanding.

What happened to Xilio Therapeutics Inc’s price movement after its last earnings report?

Xilio Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.032. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Xilio Therapeutics Inc?

Currently, no hedge funds are holding shares in XLO

Xilio Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-908.28%

Trailing 12-Months

Asset Growth

79.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xilio Therapeutics Inc

Xilio Therapeutics (XLO) is a biotechnology company focused on developing tumor-selective immuno-oncology therapies. It operates within the healthcare and biotechnology sectors, with a core emphasis on engineering therapies that localize their activity within tumors to minimize systemic toxicity. The company's proprietary technology platform is designed to enhance the therapeutic index of its drugs, aiming to offer more effective and safer cancer treatments.

Xilio Therapeutics (XLO) Earnings & Revenues

Historic Earnings Reports

XLO Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.8,0.8923076923076924,0.9846153846153847,1.0769230769230769,1.1692307692307693,1.2615384615384615,1.353846153846154,1.4461538461538461,1.5384615384615383,1.6307692307692307,1.7230769230769232,1.8153846153846154,1.9076923076923076,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.8,0.7384615384615385,0.676923076923077,0.6153846153846154,0.5538461538461539,0.49230769230769234,0.4307692307692308,0.36923076923076925,0.3076923076923077,0.24615384615384617,0.18461538461538463,0.12307692307692308,0.06153846153846154,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.8,0.8923076923076924,0.9846153846153847,1.0769230769230769,1.1692307692307693,1.2615384615384615,1.353846153846154,1.4461538461538461,1.5384615384615383,1.6307692307692307,1.7230769230769232,1.8153846153846154,1.9076923076923076,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.3,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >